Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04473690 · ClinicalTrials.gov registry record · Phase 1

KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers

A Phase 1 study of Covid19, sponsored by KBio.

Completed
Registry status
Phase 1
Development phase
102
Enrollment target
8
Study locations

NCT04473690 is a Phase 1 study of Covid19 that has completed, run by KBio. The registered enrollment target is 102 participants, below the 2,701-participant average among 94 other Covid19 trials with a reported enrollment target (96% lower). The trial reports 8 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04473690, a Phase 1 study of Covid19, has completed, sponsored by KBio.

COMPLETED
Registry status
Phase 1
Development phase
102 participants
Enrollment target
8
Study locations

Study Summary

This is an First In Human (FIH), observer-blinded, randomized, placebo-controlled, parallel group study to evaluate the safety and immunogenicity of KBP-COVID-19 plus CPG adjuvant vaccine in healthy adult subjects in 2 age groups, Part A (18-49 years) and Part B (50-85 years).

Conditions Studied

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL Low Dose of KBP-COVID-19
  • BIOLOGICAL High Dose of KBP-COVID-19

Study Locations (8)

Texas

  • PanAmerican Clinical Research - Brownsville
  • ICON - San Antonio
  • DM Clinical Research - Tomball

Florida

  • Palm Beach Research Center - West Palm Beach

Idaho

  • Velocity Clinical Research - Meridian

North Carolina

  • PMG Research of Winston-Salem - Winston-Salem

Burlington/Ontario

  • LMC Manna Research - Burlington

Point Claire, Quebec

  • LMC Manna Research - Montreal

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2020-12-30
Est. Completion 2022-10-14
Phase Phase 1

Sponsor

KBio

4 total trials

What the Registry Record Tells You About NCT04473690

The ClinicalTrials.gov registry entry for NCT04473690 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,701-participant average among 94 other Covid19 trials with a reported enrollment target (96% lower). The listed sponsor is KBio, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Covid19 appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT04473690 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Texas, Florida, Idaho.

Frequently Asked Questions

What is clinical trial NCT04473690 about?

NCT04473690 is a clinical study titled "KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers". This is an First In Human (FIH), observer-blinded, randomized, placebo-controlled, parallel group study to evaluate the safety and immunogenicity of KBP-COVID-19 plus CPG adjuvant vaccine in healthy adult subjects in 2 age groups, Part A (18-49 years) and Part B (50-85 years).

What is the current status of trial NCT04473690?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 102 participants. The study started on 2020-12-30. Estimated completion is 2022-10-14.

What conditions does trial NCT04473690 study?

This clinical trial studies the following conditions: Covid19.

What interventions are being tested in trial NCT04473690?

The interventions under investigation include: Placebo (BIOLOGICAL), Low Dose of KBP-COVID-19 (BIOLOGICAL), High Dose of KBP-COVID-19 (BIOLOGICAL).

Who is sponsoring clinical trial NCT04473690?

This trial is sponsored by KBio, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04473690 being conducted?

This trial has 8 study locations across Florida, Idaho, North Carolina, Texas, Burlington/Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Covid19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.